Improving Access to Target Cells

PRESS RELEASE, Huddinge Sweden 03-Sep-2024

OptiCell Solutions: Improving Access to Target Cells for Cell and Gene Therapy and
Therapeutic Apheresis Treatments – Huddinge, Sweden, 03-SEP-2024

As the demand for advanced personalized medicine increases, OptiCell Solutions, an
innovative actor, introduces cutting-edge solutions to meet the critical needs within the
healthcare and the pharmaceutical industries.
The company specializes in the collection and delivery of high-quality cell collections
and the performance of therapeutic apheresis treatments, two areas where there is a
significant lack of resources. “We often struggle to get healthcare to collect cells from
our donors”, says Mats Bengtsson, medically responsible physician with many years’
experience in stem cell donation.

Innovation in Cell and Gene Therapy (CAGT)
OptiCell Solutions possesses extensive knowledge of study coordination which includes
specific research ethics within CAGT and enhances innovative research and
development of new therapies with high capacity to deliver quality cells to clinical
researchers and the pharmaceutical industry.
“We want to be actively involved in the development of Advanced Therapy Medicinal
Products (ATMPs) by offering our high-quality cell collections for research in CAGT – the
fastest growing segment within precision medicine – and focus on collecting target cells
with our unique expertise in research ethics in apheresis technology to give researchers
an excellent starting point in the development of new treatment therapies for cancer and
autoimmune diseases,” says Jarmo Henriksson, CEO at OptiCell Solutions.

Meeting Critical Needs in Swedish Healthcare
Swedish healthcare faces major challenges with an aging population and increasing
demand for specialized medical treatments. OptiCell Solutions establishes itself as a
critical resource by offering improved access to both cell collections and therapeutic
apheresis treatments, essential for patients suffering from severe diseases and
conditions where treatment cannot wait.

Commitment to Patient Care
By shortening waiting times for apheresis treatments and increasing the availability of
essential target cells for CAGT development, the company contributes to improved
patient care and faster treatment times. “Our ambition is that the patient should not
have to wait for vital treatments. With our unique expertise and dedicated team, we
make this possible,” adds Jarmo Henriksson.

For more information, contact Jarmo Henriksson by phone: +46 (0) 73 699 48 37, or by
email: jarmo@opticellsolutions.com

—END PRESS RELEASE—

PRESS RELEASE 03SEP2024

About OptiCell Solutions

Founded in 2024, OptiCell Solutions AB specializing in the field of apheresis and cell collection for gene and cell therapies (CAGT). By using our advanced apheresis technology, we can collect large quantities of specific donor cells, significantly advancing CAGT applications within in the biotech and healthcare sector. Furthermore, our extensive experience and know-how in apheresis enable us to offer specialized therapeutic apheresis service to the healthcare sector. We are providing the industry and healthcare sector with services in setting up and coordinating clinical trials in the CAGT field.
Located near the Karolinska University Hospital in Huddinge we aim to bridge the gap in resources by offering innovative solutions that enhance the availability of essential cells for groundbreaking research and life-saving therapies. With our deep expertise in apheresis technology and a strong commitment to ethical research practices, we are dedicated to improving patient outcomes and supporting the development of next-generation therapies for cancer, autoimmune diseases, and other severe medical conditions.

At OptiCell Solutions, we strive to be at the forefront of medical innovation, providing the tools and services necessary to accelerate the transition to more effective and patient-centred care.

Explanations

Cell Collection
• Collection of donor cells is performed through peripheral cell donation using an
apheresis machine where the blood is directed from a person to the machine and
then back to the person. The machine separates the desired target cells from the
rest of the blood into a collection bag through a closed system.

Therapeutic Apheresis Treatments
• Acute or chronic medical condition requiring treatment with an extracorporeal
blood purification procedure in which blood is drawn from a patient, either by
centrifuge or column technique, to selectively or semi-selectively remove
pathogenic components from the patient’s blood or plasma. The blood is then
returned to the patient in a closed system.

Precision Medicine
• Future healthcare enabling tailored prevention, diagnosis, treatment, and follow
up, based on the individual patient’s unique conditions.

Cell and Gene Therapy (CAGT)
• A field within biomedical research and treatment aimed at treating, preventing, or
potentially curing diseases including cancer care.

ATMPs
• Advanced Therapy Medicinal Products, biological drugs based on cells, tissues,
and genes. Advanced therapies can treat diseases in entirely new ways.

Apheresis Technology
• The science of apheresis machine, apheresis technique, apheresis methodology
related to healthcare and research where apheresis treatments are performed.

Fact

• In the 2020s, those born in the 1940s will be or become over 80 years old. This
means a greater need for care and services – 500,000 people who are +80 years are estimated to become 750,000 people by 2030 (SCB 2024)